Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to heart failure with a focus on LVEF ≥ 40%. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated April 20, 2026.

Types of Enhancements Available

audio
Audio
infographic
Graphical Abstract
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 106    

Filtered results: 106

Time in Blood Pressure Range and Cardiovascular Outcomes in HFmrEF/HFpEF: Pooled Participant-Level Analysis of Four Large-Scale Trials

Lu, H. et al., EJHF 2026

Henry Lu, 27 10 2026

Practical Implementation of Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists in the Management of Heart Failure

Michos E, et al., SD. 2026

Erin D. Michos, 20 10 2026

Effectiveness of Finerenone in Slowing Chronic Kidney Disease Progression After Hospitalization for Heart Failure: A FIDELITY Subgroup Analysis

Shafi T, et al, EJHF. 2026

Tariq Shafi, 25 09 2026

Undiagnosed Chronic Kidney Disease, Outcomes, and Finerenone in Heart Failure: The FINEARTS-HF Randomized Clinical Trial

Ostrominski J, et al., JAMA Card. 2026

John W. Ostrominski , 22 09 2026

HFpEF-ABA Score and Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Insights From the FINEARTS-HF Trial

Ono R, et al., JACC HF. 2026

Ryohei Ono, 21 09 2026

Finerenone and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Ostrominski, EJOHF., et al, PM. 2026

Ostrominski, JW , 28 08 2026

Finerenone Benefits in Patients With Cardio-Kidney-Metabolic Syndrome With or Without History of Cancer: The Fine-Heart Pooled Analysis

Ruppert M., et al, EHJ. 2026

Ruppert, M, 28 08 2026

Contemporary Medical Therapy for Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Beavers CJ., et al, PM. 2026

Beavers, CJ, 27 08 2026

Finerenone and Blood Pressure in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial

Ostrominski J., et al, JAMA. 2026

Ostrominski J, 08 07 2026

Effects of Finerenone on Sudden Death Across the Cardio-Kidney-Metabolic Landscape: A FINE-HEART Analysis

Foà A, et al, JAMA. 2026

Foa A, 08 06 2026